Renata

DSE: RENATA

Pharmaceuticals · Renata (ex-Pfizer)

Renata PLC is an established Bangladeshi pharmaceutical and animal-health company that traces its origins to the local operations formerly run by Pfizer. It is one of the older listings on the Dhaka Stock Exchange.

Business: Manufacturing and marketing of human pharmaceutical formulations and animal-health/nutrition products, with a growing export presence.

Market data

Paid-up capital

1,147 mn BDT

Outstanding shares

114,696,490

Listed

1979

Source: Dhaka Stock Exchange, fetched 2026-05

Policy exposure

Pharmaceutical drug-pricing and essential-medicine policy As a long-standing producer, its pricing within the regulated essential-drug framework affects affordability and the regulator's price-control stance. Source: analysis

API import dependence and forex exposure Reliance on imported active ingredients links the firm's costs to exchange-rate conditions, supporting the case for domestic API-park policy. Source: analysis

LDC graduation and patent transition The end of the TRIPS pharmaceutical waiver after graduation affects the generics and animal-health export model, a sector-wide transition concern. Source: analysis